WT1 126-134 peptide

BIOLOGICAL2 trials

Sponsors

Charite University, Berlin, Germany

Conditions

Acute Myeloid LeukemiaMyelodysplastic SyndromeWT1 Expressing Carcinoma

Phase 2

WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)

Charite University, Berlin, GermanyAcute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2002-04-30Target: 25Updated: 2006-02-22

WT1 Peptid Vaccination in Carcinomas

Charite University, Berlin, GermanyWT1 Expressing Carcinoma

Start: 2004-04-30Target: 25Updated: 2006-02-14

Related Papers

Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.

2010-01-2112 citations